B2BROKER Introduces PrimeXM XCore Support & Maintenance Services for Brokers
19.2.2025 12:56:00 CET | Business Wire | Press release
B2BROKER has announced the launch of its PrimeXM XCore support and maintenance services, expanding its suite of technology solutions for brokers and financial institutions. This new solution complements the company’s existing support offerings for trading platforms, including cTrader, MT4, and MT5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217935952/en/
B2BROKER's PrimeXM XCore Service provides complete support to manage all technical aspects, including setup and ongoing maintenance, of the PrimeXM XCore server. (Graphic: Business Wire)
PrimeXM XCore in the Trading Industry
PrimeXM’s XCore is a widely used trading and aggregation engine, serving over 250 financial institutions worldwide. It provides ultra-low latency order execution, risk management capabilities, and advanced reporting tools while supporting multi-asset trading across multiple venues.
As a key component in modern brokerage infrastructure, XCore offers brokers improved liquidity access and streamlined execution. However, maintaining and managing the system can be resource-intensive, often requiring the recruitment and training of specialised personnel. Establishing an in-house team to operate XCore typically involves significant time and financial investment.
B2BROKER’s Managed PrimeXM XCore Services
Recognising the operational challenges, B2BROKER has introduced a fully managed PrimeXM XCore service designed to reduce brokers' workloads.
The new service ensures that industry professionals handle all technical aspects of the system, from setup to ongoing maintenance. This allows brokers to focus on business development and client service.
Additionally, B2BROKER introduces a dedicated audit service for clients with an existing PrimeXM server. This service involves a thorough assessment of the setup and detailed recommendations to optimise system performance and ensure a seamless transition under the company’s maintenance.
Arthur Azizov, CEO and Founder of B2BROKER, says:
"We provide comprehensive support to manage all technical aspects of PrimeXM XCore, including setup, ongoing maintenance, and day-to-day operations. No matter the number or type of liquidity providers a broker works with, B2BROKER guarantees seamless trading operations."
Clive Diethelm, CEO and Founder of PrimeXM, comments:
"By collaborating with B2BROKER, we aim to enhance our offerings with flexible support models, ensuring clients can choose solutions that best fit their requirements."
Key Features of the Service
The service package provided by B2BROKER includes:
- Comprehensive System Configuration – Full setup of trading infrastructure, including instruments, asset classes, and user access management.
- Secure Connectivity – Secure and stable integration with liquidity providers and trading venues to ensure seamless execution.
- Customisable Trading Parameters – Adaptation of trading and routing rules to align with each broker’s operational model.
- Continuous Monitoring & Support – 24/7 system oversight to maintain stability and rapid issue resolution.
- Automated Performance Reports – Generation of daily and monthly reports offering insights into system performance and trading efficiency.
Summary
By introducing this service, B2BROKER aims to simplify technical management for brokers relying on PrimeXM XCore. The fully managed approach reduces operational complexities, minimises costs associated with in-house maintenance, and ensures uninterrupted trading operations.
For brokers seeking a reliable and efficient way to manage their PrimeXM XCore infrastructure, B2BROKER’s new service provides a structured solution backed by industry expertise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217935952/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom